Biologics Webinar: Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors (英語)
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immunostimulatory checkpoint receptors have proved to be powerful agents to restore anti-tumor immune responses, such as anti-PD1 therapy. However, developing drugs targeting these checkpoint proteins has proved to be quite challenging as cell-based assays used to screen for functional drugs are often difficult to create, involve the use of human blood-derived cells, and have long, complicated protocols.
Here, we introduce the PathHunter® Checkpoint assay portfolio, which solves this bottleneck with an expanding menu of cell-based assays that enables screening and potency assays for immunotherapy drugs. These biologically relevant cell-based assays do not require human blood-derived cells, have a simple protocol, and provide a highly sensitive response in less than 5 hours. Assays discussed will include PD-1 (with PD-L1 and PD-L2), OX-40, CD40, TWEAK, and VISTA.
What will be covered?
- Novel cell-based assays for checkpoint signaling receptors
- PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others
- Functional assays for biologics and small molecule screening
- Applications for QC lot release testing of biologics
ウェブセミナー 録音版はこちらから★
ウェブセミナー パワーポイント資料はこちらから★
2016年2月17日収録分
｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ｡*ﾟ*｡，｡*
★DiscoverX社では、創薬に役立つ技術・サービスに関するニュースレターを配信しています。配信をご希望の方は下記フォームよりお知らせください。
★GPCRリファレンスガイドブック・リクエストはこちらから
★【The Druggable GPCRome】ポスターを進呈中
ご意見・ご質問は、お問い合わせフォームからお気軽にどうぞ。
★DiscoverX社では、創薬に役立つ技術・サービスに関するニュースレターを配信しています。配信をご希望の方は下記フォームよりお知らせください。
★GPCRリファレンスガイドブック・リクエストはこちらから
★【The Druggable GPCRome】ポスターを進呈中
ご意見・ご質問は、お問い合わせフォームからお気軽にどうぞ。
｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ*｡，｡*ﾟ｡*ﾟ*
0 件のコメント:
コメントを投稿